Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
New AI tool aims to detect early signs of dementia during routine eye tests
-
LifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs
-
Third global Longitude Prize to be launched in 2025 focusing on ALS